Amendment: SEC Form SC 13G/A filed by Genelux Corporation

$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GNLX alert in real time by email
SC 13G/A 1 tm2426664d1_sc13ga.htm SC 13G/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

GENELUX CORPORATION

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

36870H103

(CUSIP Number)

 

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)
     
  ¨ Rule 13d-1(c)
     
  x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 36870H103 Schedule 13G Page 2 of 5

 

1

NAME OF REPORTING PERSON

 

Aladar Szalay

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ¨ (b) ¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING PERSON WITH:

5

SOLE VOTING POWER

 

3,408,581 (1)

6

SHARED VOTING POWER

 

5,000 (2)

7

SOLE DISPOSITIVE POWER

 

3,408,581 (1)

8

SHARED DISPOSITIVE POWER

 

5,000 (2)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,413,581 (3)

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

9.9% (4)

12

TYPE OF REPORTING PERSON

 

IN

 

(1) Consists of (i) 599,821 shares of common stock held by The Szalay 2010 Retained Annuity Trust, (ii) 2,258,760 shares of common stock held by The Szalay 2009 Irrevocable Trust and (iii) 550,000 shares of common stock held by The Szalay 2010 Children’s Trust, for which the reporting person has sole voting and dispositive power.
(2) Consists of 5,000 shares of common stock held by the reporting person’s spouse, for which the reporting person has shared voting and dispositive power.
(3) Consists of (i) 599,821 shares of common stock  held by The Szalay 2010 Retained Annuity Trust, (ii) 2,258,760 shares of common stock held by The Szalay 2009 Irrevocable Trust and (iii) 550,000 shares of common stock held by The Szalay 2010 Children’s Trust, for which the reporting person has sole voting and dispositive power, and (iv) 5,000 shares of common stock held by the reporting person’s spouse, for which the reporting person has shared voting and dispositive power.
(4) This percentage is calculated based on 34,535,471 shares of common stock outstanding as of August 12, 2024, as reported in Genelux Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 14, 2024.

 

 

 

 

CUSIP No. 36870H103 Schedule 13G Page 3 of 5

 

Item 1(a).

Name of Issuer:

Genelux Corporation

   
Item 1(b).

Address of Issuer’s Principal Executive Offices:

2625 Townsgate Road, Suite 230

Westlake Village, California 91361

   
Item 2(a).

Names of Person Filing:

 

Aladar Szalay

   
Item 2(b).

Address of Principal Business Office, or, if none, Residence:

 

  7704 North Fork Rd., Highland, CA 92346
   
Item 2(c).

Citizenship:

 

United States

 

Item 2(d).

Title of Class of Securities:

 

Common Stock, par value $0.001 per share

   
Item 2(e).

CUSIP No.:

 

36870H103

 

Item 3. Not Applicable.

 

Item 4. Ownership.

 

  (a) Amount beneficially owned:
     
    See Row 9 of cover page.

 

  (b) Percent of class:
     
    See Row 11 of cover page.

 

  (c) Number of shares as to which the person has:

 

  (i) Sole power to vote or to direct the vote:
     
    See Row 5 of cover page for the Reporting Person.

 

  (ii) Shared power to vote or to direct the vote:
     
    See Row 6 of cover page for the Reporting Person.

 

  (iii) Sole power to dispose or to direct the disposition of:
     
    See Row 7 of cover page for the Reporting Person.

 

  (iv) Shared power to dispose or to direct the disposition of:
     
    See Row 8 of cover page for the Reporting Person.

 

 

 

 

CUSIP No. 36870H103 Schedule 13G Page 4 of 5

 

Item 5. Ownership of Five Percent or Less of a Class.

 

Not Applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10. Certifications.

 

Not Applicable.

 

 

 

 

CUSIP No. 36870H103 Schedule 13G Page 5 of 5

 

SIGNATURE

 

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: October 22, 2024  
   
       /s/ Aladar Szalay
  Aladar Szalay

 

 

Get the next $GNLX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GNLX

DatePrice TargetRatingAnalyst
10/29/2024$8.00Buy
Guggenheim
8/28/2024$10.00Buy
ROTH MKM
11/27/2023$35.00Buy
H.C. Wainwright
9/12/2023$40.00Buy
Maxim Group
2/15/2023$10.00Speculative Buy
The Benchmark Company
More analyst ratings

$GNLX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates. "Our pr

    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

    WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. The net proceeds from the offering are to be used for working capital and for general corporate purp

    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

    –  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. –  Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 29.2%. –  Data are supportive of Olvi-Vec being a platinum resensitizing agent beyond ovarian cancer and, consistent with earlier studies, being systemically administered in multiple solid tumo

    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GNLX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GNLX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GNLX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GNLX
SEC Filings

See more

$GNLX
Leadership Updates

Live Leadership Updates

See more
  • Genelux Corporation Announces New Chief Financial Officer

    WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GNLX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$GNLX
Insider purchases explained

Analytical look into recent insider purchases

See more
  • What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care